These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3931923)
21. Activity of ceftazidime and newer antibiotics against Gram-negative bacilli. Schassan HH; Fedder J J Antimicrob Chemother; 1981 Sep; 8 Suppl B():79-82. PubMed ID: 19802973 [TBL] [Abstract][Full Text] [Related]
22. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005]. Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265 [TBL] [Abstract][Full Text] [Related]
23. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
24. A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships. Yamawaki K; Nomura T; Yasukata T; Uotani K; Miwa H; Takeda K; Nishitani Y Bioorg Med Chem; 2007 Nov; 15(21):6716-32. PubMed ID: 17723304 [TBL] [Abstract][Full Text] [Related]
25. Antibacterial and antioxidant activities in Sideritis italica (Miller) Greuter et Burdet essential oils. Basile A; Senatore F; Gargano R; Sorbo S; Del Pezzo M; Lavitola A; Ritieni A; Bruno M; Spatuzzi D; Rigano D; Vuotto ML J Ethnopharmacol; 2006 Sep; 107(2):240-8. PubMed ID: 16690235 [TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates. Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506 [TBL] [Abstract][Full Text] [Related]
27. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs. Fass RJ Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270 [TBL] [Abstract][Full Text] [Related]
28. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates]. Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135 [TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [TBL] [Abstract][Full Text] [Related]
30. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Jones RN; Sader HS; Fritsche TR Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447 [TBL] [Abstract][Full Text] [Related]
31. Determination of the postantibiotic effect of ofloxacin on gram-negative bacteria utilizing a new method. Nilsson L; Isaksson B; Maller R; Nilsson M J Chemother; 1989 Jul; 1(4 Suppl):149-51. PubMed ID: 16312347 [No Abstract] [Full Text] [Related]
32. [Comparative bactericidal activity of beta-lactam-aminoglycoside combinations against Pseudomonas aeruginosa]. Cluzel M; Chanal M; Sirot J; Cluzel R Nouv Presse Med; 1982 Nov; 11(46):3400-4. PubMed ID: 6818523 [TBL] [Abstract][Full Text] [Related]
33. [Application of a millipore membrane transfer method to the study of the activity of 4 beta-lactams on Pseudomonas aeruginosa]. Denis C; Lesage D; Delisle-Mizon F; Vergez P; Daguet GL Pathol Biol (Paris); 1984 May; 32(5):415-20. PubMed ID: 6429614 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Sader HS; Jones RN Int J Antimicrob Agents; 2005 Feb; 25(2):95-109. PubMed ID: 15664479 [TBL] [Abstract][Full Text] [Related]
35. [Non-fermentative Gram-negative bacilli of human origin. II. In vitro sensitivity of 185 strains to 17 anti-microbial agents]. Paredes L; Thompson L; del Canto E; Paredes L Rev Med Chil; 1985 Sep; 113(9):878-85. PubMed ID: 3837315 [No Abstract] [Full Text] [Related]
36. In vitro activity of CI-934 and other antimicrobial agents against gram-positive and gram-negative bacteria. Smith RP; Baltch AL; Hammer MC; Conroy JV Clin Ther; 1986; 9(1):106-18. PubMed ID: 3815456 [TBL] [Abstract][Full Text] [Related]
37. Activity of ceftazidime against Gram-negative bacilli from paediatric patients. Nelson JD; Shelton S J Antimicrob Chemother; 1981 Sep; 8 Suppl B():179-81. PubMed ID: 19802983 [TBL] [Abstract][Full Text] [Related]
38. [In vitro antimicrobial activity of CI-919 against gram-negative bacilli and Staphylococcus aureus isolated from various pathologies]. Prado V; Reyes L Rev Med Chil; 1985 Feb; 113(2):94-102. PubMed ID: 3866270 [No Abstract] [Full Text] [Related]
39. A predictive parameter of antibacterial efficacy in vivo, based on efficacy in vitro and pharmacokinetics. Mattie H Scand J Infect Dis Suppl; 1990; 74():133-6. PubMed ID: 2129065 [TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group. Blondeau JM; Laskowski R; Borsos S J Antimicrob Chemother; 1999 Oct; 44(4):545-8. PubMed ID: 10588318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]